Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pneumococcal conjugate vaccine.

M Ledwith1

  • 1Causeway Hospital, Coleraine, County Londonderry, Northern Ireland. michael.ledwith@chsst.n-i.nhs.uk

Current Opinion in Pediatrics
|February 15, 2001
PubMed
Summary

New conjugate pneumococcal vaccines offer safe and effective protection for infants, addressing antimicrobial resistance. These vaccines provide a stronger immune response than older types, crucial for young children at high risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of rabies exposure in pediatric practice.

Current opinion in pediatrics·1997
Same author

Clinical course of pertussis in immunized children.

The Pediatric infectious disease journal·1995
Same author

A database management system for residency applicant files.

Computers and biomedical research, an international journal·1988
Same author

The perception of control in loud noise.

Perception·1984

Area of Science:

  • Pediatric infectious diseases
  • Vaccinology
  • Microbiology

Background:

  • Pneumococcal infections are a major cause of bacterial illness in children.
  • Increasing antimicrobial resistance in Streptococcus pneumoniae necessitates novel prevention strategies.
  • Existing polysaccharide vaccines are ineffective in infants under two years old.

Purpose of the Study:

  • To evaluate the effectiveness and safety of protein-conjugated pneumococcal vaccines.
  • To assess the potential of conjugate vaccines in preventing otitis media and reducing nasopharyngeal carriage.
  • To highlight the benefits of conjugate vaccines for high-risk infant populations.

Main Methods:

  • Review of published clinical trials on protein-conjugated pneumococcal vaccines.
  • Analysis of immunogenicity data, focusing on infant responses.
  • Assessment of safety profiles and efficacy against pneumococcal disease and related conditions.

Main Results:

  • Protein-conjugated pneumococcal vaccines demonstrate effectiveness and safety in clinical trials.
  • These vaccines induce a robust and rapid immune response, superior to older formulations.
  • Conjugate vaccines show promise in preventing otitis media and decreasing nasopharyngeal carriage of pneumococci.

Conclusions:

  • Protein-conjugated pneumococcal vaccines represent a significant advancement in pediatric infectious disease prevention.
  • The strategy, supported by successful Haemophilus influenzae type b conjugate vaccines, is effective for infants.
  • Widespread adoption of these conjugate vaccines is deemed safe, cost-effective, and crucial for public health.

Related Experiment Videos